Revive Therapeutics and NanoPalm to Collaborate on Cancer Therapeutics

Revive Therapeutics has signed a letter of intent to form a joint venture with Saudi-based NanoPalm to co-develop cancer therapeutics. The joint venture aims to develop and commercialize new cancer treatments. The collaboration is expected to leverage the expertise of both companies in the field of cancer research and therapy.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has signed a non-binding Letter of Intent (LOI) with Saudi-based NanoPalm Ltd. to form a joint venture aimed at co-developing and commercializing novel cancer therapeutics. The collaboration leverages the expertise of both companies in cancer research and therapy, with the potential to create a robust pipeline of new treatments.

The joint venture will focus on developing and advancing small-molecule oncology therapeutics, beginning with the dual-function PARP-HDAC inhibitor, kt3283. NanoPalm's patented patterned lipid nanoparticle (pLNP) delivery system will be used to enhance the precision and efficacy of therapeutic delivery, potentially improving the compound's therapeutic index and tumor-specific delivery.

Revive Therapeutics brings to the table its proprietary AI-enabled drug discovery engine, which uses an exclusive license to the Deep Docking™ platform to rapidly screen billions of molecules against validated cancer targets. NanoPalm, on the other hand, offers its advanced pLNP technology, originally developed for gene therapy, which uses AI-assisted formulation design to improve tissue specificity and intracellular delivery.

The joint venture is expected to initially focus on advancing kt3283 through late preclinical development and early clinical studies, while evaluating additional AI-derived drug candidates for inclusion in the development pipeline. The partners also plan to explore global licensing and strategic commercialization opportunities as the pipeline matures.

The collaboration represents an initial oncology application of NanoPalm's proprietary platform to small-molecule therapeutics, offering the potential to significantly enhance the delivery profile of small-molecule therapies. This partnership aligns with the Kingdom of Saudi Arabia's National Biotechnology Strategy, aiming to innovate and accelerate local biotech development.

The joint venture is expected to have significant implications for both companies, as well as the broader oncology market. The collaboration brings together two innovative platforms, combining advanced drug discovery capabilities with cutting-edge delivery technologies, to create a seamless path from in silico modeling to formulation to preclinical proof of concept.

References

1. [Revive Therapeutics Announces Closing of First Tranche of Private Placement Offering](https://www.stocktitan.net/news/RVVTF/revive-therapeutics-announces-closing-of-first-tranche-of-private-oqtkrkjls0p4.html)
2. [Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture](https://www.globenewswire.com/news-release/2025/08/12/3131449/0/en/Rakovina-Therapeutics-and-NanoPalm-Ltd-Sign-Letter-of-Intent-to-Form-Joint-Venture-Leveraging-AI-Discovered-Oncology-Therapies-and-Novel-Lipid-Nanoparticle-Delivery-Technologies.html)